FDA-related news items of relevance from the month of June, 2013.
Denosumab improved overall survival in persons with lung cancer and bone metastases more effectively than did zoledronic acid.
When patients with giant-cell tumor of the bone were treated with denosumab, which is a drug targeted against a protein that promotes bone destruction, the number of tumor giant cells decreased and new bone formation increased.
- Coping With Lymphedema: A Patient Guide (Fact Sheet)
- Osteoporosis Medication Improves Bone Health in ADT-Treated Prostate Cancer
- Inotuzumab Ozogamicin Granted FDA Approval for Acute Lymphoblastic Leukemia
- Cabazitaxel in Prostate Cancer: Reduced Dose Noninferior to Standard Dose
- Risk of Some Cancers Higher in Women With a History of Periodontal Disease
- To Better Serve Patients With Cancer, Navigators Need Better Systems
- Physical Activity Improves Cognitive Function for Breast Cancer Survivors
- Risk of Lung Cancer Increases With Diets Higher in Saturated Fats
- Mechanisms Identified for Curcumin Resensitization of Cancer Cells
- Value of Type and Crossmatch Prior to Daratumumab Administration
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|